Ultime notizie per Aptorum Gr (NASDAQ:APM) Azioni

Aptorum Gr

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group Ltd

apM Coin

MORIEN RESOURCES CORP ORD by Morien Resources Corp.

Morien Resources Corp

EAGLE GRAPHITE INC by Eagle Graphite Inc.

APM HUMAN SVCS INTL PTY by APM HUMAN SVCS INTL PTY LTD.

ApartmentLove Inc

ASPERMONT LTD by ASPERMONT LTD.

Amper SA

Aperam SA

APERAM ORD

Trust for Professional Managers ActivePassive Intermediate Municipal Bond ETF

<p>JP Morgan  analyst Kenneth Worthington   maintains Franklin Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>) with a Neutral and lowers the price target from $22 to $21.</p>


News

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on Franklin Resources, Lowers Price Target to $21

WIIM

UFPT

UFP Technologies shares are trading higher after the company reported better-than-expected Q3 financial results.

<p><strong>Blink Charging Co.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) shares are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading higher on Tuesday.</a></p>
<p>Today, the company has unveiled the creation of a Special Purpose Vehicle (SPV) designed to expand EV charging infrastructure<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41745007/blink-to-establish-a-100-million-special-purpose-vehicle-to-drive-electric-vehicle-charger-investm" rel="noreferrer noopener"> in the U.K. and beyond.</a></p>
<p>The SPV aims to raise an initial £100 million ($130.10 million), offering investors the chance to capitalize on the rapidly growing EV infrastructure market.</p>
<p>To kick off the project, Blink has partnered with Axxeltrova Capital, a private equity firm focused on digital infrastructure, renewable energy, and sustainable investments. This makes it the SPV&#8217;s first funding partner.</p>
<p>&#8220;While we are in the early stages and agreements are still being formalized, the potential for growth in the EV sector is unmistakable,&#8221; said Mike Battaglia, CEO-Elect of Blink Charging.</p>
<p>&#8220;We invite other investors to join us in this exciting opportunity to shape the future of electric mobility.&#8221;</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41748807/thomson-reuters-q3-earnings-legal-corporate-segments-enjoy-revenue-boost-as-ceo-highlights-ai-inves" rel="noreferrer noopener">Thomson Reuters Q3 Earnings: Legal, Corporate Segments Enjoy Revenue Boost As CEO Highlights AI Investment</a></strong></p>
<p>The SPV&#8217;s structure is designed to attract further investments, enabling Blink to deploy significant capital to expand accessible charging networks.</p>
<p>The SPV targets projects eligible for subsidies through the UK&#8217;s Local Electric Vehicle Infrastructure (LEVI) funding.</p>
<p>Recently, the firm disclosed that it has received a nearly $2 million grant from the Illinois&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41624237/blink-charging-awarded-2-million-grant-to-provide-ev-chargers-for-state-of-illinois" rel="noreferrer noopener">Environmental Protection Agency</a>.</p>
<p>This funding will enable Blink to own and operate EV chargers in the state of Illinois, facilitating public charging solutions for employees, residents, and visitors.</p>
<p>Under this grant, the Illinois EPA will cover part of the eligible expenses for new commercial-grade DC Fast Chargers and Alternating Current Level 2 charging stations to be installed at publicly accessible locations throughout Illinois.</p>
<p>Once completed, the project will feature 15 new Blink charging stations across five sites in Illinois, including 10 DC fast chargers with 180kW capacity and five Dual Port Level 2 stations (10 ports total). Blink is contributing a 30% cost share to the program.</p>
<p><strong>Price Action:&nbsp;</strong>BLNK shares are up 2.99%&nbsp;at&nbsp;$2.07&nbsp;at the last check Tuesday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/equities/24/10/41631517/blink-to-deploy-15-new-ev-charging-stations-in-illinois-backed-by-2-million-state-grant" target="_blank" rel="noreferrer noopener">Blink To Deploy 15 New EV Charging Stations In Illinois, Backed By $2 Million State Grant</a></strong></li>
</ul>


Equities

Markets

Movers

General

BLNK

What's Going On With Blink Charging Stock Tuesday?

<p>Financial giants have made a conspicuous bearish move on CrowdStrike Holdings. Our analysis of options history for CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) revealed 19 unusual trades.</p>
<p>Delving into the details, we found 26% of traders were bullish, while 47% showed bearish tendencies. Out of all the trades we spotted, 11 were puts, with a value of $449,009, and 8 were calls, valued at $674,910.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $185.0 and $340.0 for CrowdStrike Holdings, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for CrowdStrike Holdings's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across CrowdStrike Holdings's significant trades, within a strike price range of $185.0 to $340.0, over the past month.</p>
<h3>CrowdStrike Holdings Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730823366_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$120.3</td>
<td>$118.25</td>
<td>$118.25</td>
<td>$185.00</td>
<td>$260.1K</td>
<td style="text-align: right;">36</td>
<td style="text-align: right;">22</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$136.55</td>
<td>$126.65</td>
<td>$130.63</td>
<td>$220.00</td>
<td>$130.5K</td>
<td style="text-align: right;">112</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$81.8</td>
<td>$80.8</td>
<td>$81.8</td>
<td>$250.00</td>
<td>$81.8K</td>
<td style="text-align: right;">57</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>CRWD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$37.55</td>
<td>$37.25</td>
<td>$37.55</td>
<td>$310.00</td>
<td>$75.1K</td>
<td style="text-align: right;">545</td>
<td style="text-align: right;">20</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$33.8</td>
<td>$33.75</td>
<td>$33.8</td>
<td>$310.00</td>
<td>$67.6K</td>
<td style="text-align: right;">646</td>
<td style="text-align: right;">21</td>
</tr>
</tbody>
</table>
</p>
<h3>About CrowdStrike Holdings</h3>
<p>CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.</p>
<p>Following our analysis of the options activities associated with CrowdStrike Holdings, we pivot to a closer look at the company's own performance.</p>
<h3>CrowdStrike Holdings's Current Market Status</h3>
<ul>
<li>With a volume of 428,874, the price of CRWD is up 0.92% at $301.62. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 21 days.</li>
</ul>
<h3>Expert Opinions on CrowdStrike Holdings</h3>
<p>In the last month, 2 experts released ratings on this stock with an average target price of $342.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Exane BNP Paribas has revised its rating downward to Neutral, adjusting the price target to $285.<br />
&#x2A; An analyst from JMP Securities downgraded its action to Market Outperform with a price target of $400. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for CrowdStrike Holdings, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

CRWD

This Is What Whales Are Betting On CrowdStrike Holdings

Yum! Brands shares are trading higher. The company reported Q3 financial results.

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>PDD Holdings</strong>.</p>
<p>Looking at options history for PDD Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) we detected 37 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 35% of the investors opened trades with bullish expectations and 54% with bearish.</p>
<p>From the overall spotted trades, 11 are puts, for a total amount of $1,051,483 and 26, calls, for a total amount of $2,542,190.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $110.0 and $190.0 for PDD Holdings, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for PDD Holdings's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across PDD Holdings's significant trades, within a strike price range of $110.0 to $190.0, over the past month.</p>
<h3>PDD Holdings 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730823361_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PDD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$6.05</td>
<td>$5.85</td>
<td>$5.85</td>
<td>$155.00</td>
<td>$818.9K</td>
<td>1.9K</td>
<td>1.4K</td>
</tr>
<tr>
<td>PDD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$22.65</td>
<td>$22.6</td>
<td>$22.64</td>
<td>$135.00</td>
<td>$221.6K</td>
<td>2.5K</td>
<td>189</td>
</tr>
<tr>
<td>PDD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$22.6</td>
<td>$22.55</td>
<td>$22.62</td>
<td>$135.00</td>
<td>$203.3K</td>
<td>2.5K</td>
<td>91</td>
</tr>
<tr>
<td>PDD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$39.65</td>
<td>$38.8</td>
<td>$39.35</td>
<td>$155.00</td>
<td>$196.7K</td>
<td>362</td>
<td>50</td>
</tr>
<tr>
<td>PDD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$35.6</td>
<td>$34.85</td>
<td>$35.4</td>
<td>$150.00</td>
<td>$177.0K</td>
<td>1.3K</td>
<td>50</td>
</tr>
</tbody>
</table>
</p>
<h3>About PDD Holdings</h3>
<p>PDD Holdings is a multinational commerce group that owns and operates a portfolio of businesses. PDD aims to bring more businesses and people into the digital economy so that local communities and small businesses can benefit from the increased productivity and new opportunities. PDD has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses.</p>
<p>Following our analysis of the options activities associated with PDD Holdings, we pivot to a closer look at the company's own performance.</p>
<h3>PDD Holdings's Current Market Status</h3>
<ul>
<li>With a volume of 2,881,166, the price of PDD is up 0.27% at $122.64. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 21 days.</li>
</ul>
<h3>What The Experts Say On PDD Holdings</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $224.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Macquarie upgraded its action to Outperform with a price target of $224. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for PDD Holdings with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Citigourp Global Markets 2% Protected Notes Linked To The Djia

Decoding PDD Holdings's Options Activity: What's the Big Picture?

<p>RBC Capital  analyst Brian Abrahams   reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Outperform and maintains $10 price target.</p>


Reiteration

BCRX

RBC Capital Reiterates Outperform on BioCryst Pharma, Maintains $10 Price Target

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Newmont</strong>.</p>
<p>Looking at options history for Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) we detected 12 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 16% of the investors opened trades with bullish expectations and 75% with bearish.</p>
<p>From the overall spotted trades, 7 are puts, for a total amount of $713,310 and 5, calls, for a total amount of $463,240.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $30.0 and $60.0 for Newmont, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for Newmont options trades today is 5097.0 with a total volume of 2,750.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Newmont's big money trades within a strike price range of $30.0 to $60.0 over the last 30 days.</p>
<h3>Newmont Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730823356_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$12.5</td>
<td>$12.4</td>
<td>$12.5</td>
<td>$57.50</td>
<td>$352.5K</td>
<td>374</td>
<td style="text-align: right;">283</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$13.5</td>
<td>$13.3</td>
<td>$13.44</td>
<td>$35.00</td>
<td>$295.6K</td>
<td>5.0K</td>
<td style="text-align: right;">220</td>
</tr>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$14.85</td>
<td>$14.75</td>
<td>$14.85</td>
<td>$60.00</td>
<td>$142.5K</td>
<td>2</td>
<td style="text-align: right;">97</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$18.85</td>
<td>$18.45</td>
<td>$18.7</td>
<td>$30.00</td>
<td>$56.1K</td>
<td>38</td>
<td style="text-align: right;">30</td>
</tr>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$12.5</td>
<td>$12.4</td>
<td>$12.5</td>
<td>$57.50</td>
<td>$55.0K</td>
<td>374</td>
<td style="text-align: right;">328</td>
</tr>
</tbody>
</table>
</p>
<h3>About Newmont</h3>
<p>Newmont is the world's largest gold miner. It bought Goldcorp in 2019, combined its Nevada mines in a joint venture with competitor Barrick later that year, and also purchased competitor Newcrest in November 2023. Its portfolio includes 17 wholly or majority owned mines and interests in two joint ventures in the Americas, Africa, Australia and Papua New Guinea. The company is expected to produce roughly 5.5 million ounces of gold in 2024 from its core mines and 6.8 million in total. It is likely to sell a number of its higher cost, smaller mines accounting for 20% of forecast sales in 2024. Newmont also produces material amounts of copper, silver, zinc, and lead as byproducts. It had about two decades of gold reserves along with significant byproduct reserves at the end of December 2023.</p>
<p>Following our analysis of the options activities associated with Newmont, we pivot to a closer look at the company's own performance.</p>
<h3>Newmont's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,499,891, with NEM's price up by 0.2%, positioned at $45.85.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 107 days.</li>
</ul>
<h3>Expert Opinions on Newmont</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $59.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from UBS downgraded its rating to Neutral, setting a price target of $54.<br />
&#x2A; An analyst from Raymond James has decided to maintain their Outperform rating on Newmont, which currently sits at a price target of $66.<br />
&#x2A; Reflecting concerns, an analyst from Scotiabank lowers its rating to Sector Perform with a new price target of $55.<br />
&#x2A; An analyst from RBC Capital persists with their Sector Perform rating on Newmont, maintaining a target price of $53.<br />
&#x2A; An analyst from UBS persists with their Buy rating on Newmont, maintaining a target price of $67. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Newmont options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Newmont Unusual Options Activity For November 05

ARIS

Aris Water Solutions shares are trading higher after the company reported better-than-expected Q3 financial results.

<p>JP Morgan  analyst Cory Carpenter   maintains EverQuote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVER#NASDAQ">EVER</a>) with a Overweight and lowers the price target from $34 to $28.</p>


EVER

JP Morgan Maintains Overweight on EverQuote, Lowers Price Target to $28

<p>B. Riley Securities  analyst Zach Cummins   maintains QuinStreet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNST#NASDAQ">QNST</a>) with a Buy and raises the price target from $24 to $32.</p>


QNST

B. Riley Securities Maintains Buy on QuinStreet, Raises Price Target to $32

<p><strong>Payoneer Global Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYO#NASDAQ">PAYO</a>) reported third-quarter financial results before the market open on Tuesday. Here&#8217;s a <a href="https://www.benzinga.com/pressreleases/24/11/b41741854/payoneer-reports-third-quarter-2024-financial-results">rundown of the report</a>.</p>
<ul>
<li><strong>Q3 Revenue:</strong> $248.27 million, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $225.48 million</li>
</ul>
<ul>
<li><strong>Q3 EPS:</strong> 11 cents, versus estimates of 4 cents</li>
</ul>
<p>Payoneer reported $1.4 billion&nbsp;of spend on Payoneer cards in the third quarter, up&nbsp;41%&nbsp;year-over-year. The company also reported record quarterly volume, up 25% year-over-year. </p>
<p>&#8220;Payoneer delivered record quarterly volume and revenue, and significant profitability in the&nbsp;third quarter.&nbsp;We are building a full-service financial stack for global cross-border SMBs and accelerating growth and profitability across our business,&#8221; said <strong>John Caplan</strong>, CEO of Payoneer.</p>
<p>&#8220;We are at the beginning of our growth trajectory and are focused on consistent execution to capture the opportunity ahead of us.&#8221;</p>
<p><strong>See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41746843/bond-market-fear-gauge-soars-to-1-year-high-ahead-of-us-election-results-bond-vigil">Bond Market Fear Gauge Soars To 1-Year High Ahead Of US Election Results: &#8216;Bond Vigilantes Have Been Voting Early&#8217;</a></strong></p>
<p><strong>Outlook:</strong> Payoneer raised its full-year 2024 revenue guidance from a range of $920 million to $930 million to a new range of $950 million to $960 million, versus estimates of $928.71 million, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.</p>
<p>The company also raised its full-year adjusted EBITDA expectations from a range of $225 million to $235 million to a new range of $255 million to $265 million. </p>
<p><strong>PAYO Price Action:</strong> <a href="http://benzinga.com/quote/payo">Payoneer shares</a> were up 16.8% at $9.95 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.</p>
<p><em>Photo: Shutterstock.</em></p>


Earnings

Guidance

PAYO

Payoneer Stock Jumps On Q3 Earnings: The Details

ESLT

Elbit Systems shares are trading higher after the company announced that it was awarded a follow-on contract of approximately $127 million to supply Iron Fist Active Protection Systems to General Dynamics Ordnance and Tactical Systems for upgrades to the U.S. Army's Bradley M2A4E1 Infantry Fighting Vehicles.

<p>B. Riley Securities  analyst Alex Rygiel   reiterates MasTec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) with a Buy and raises the price target from $151 to $166.</p>


B. Riley Securities Reiterates Buy on MasTec, Raises Price Target to $166

<p>JP Morgan  analyst Matthew Boss   maintains Bowlero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOWL#NYSE">BOWL</a>) with a Overweight and lowers the price target from $16 to $15.</p>


BOWL

JP Morgan Maintains Overweight on Bowlero, Lowers Price Target to $15

<p>RBC Capital  analyst Ben Hendrix   maintains Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) with a Outperform and lowers the price target from $697 to $633.</p>


RBC Capital Maintains Outperform on Chemed, Lowers Price Target to $633

<p><strong>Dogecoin's</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) single-day 11% surge has sparked speculation in the cryptocurrency community if a strong bullish run is possible in case of a <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41744889/kamala-harris-backed-by-polymarkets-top-3-all-time-traders-but-two-of-them-have-hedged-the">Trump election win</a>.</p>
<p><strong>What Happened:</strong> Crypto chart analyst Ali Martinez flagged a &#8220;Sell&#8221; signal on Dogecoin's 4-hour chart, forecasting a potential correction to $0.161 or $0.156. <a href="https://twitter.com/ali_charts/status/1853448113719247312">According to</a> Ali Martinez, Dogecoin's user base continues to grow, with over 35,000 new DOGE addresses being created daily.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">The TD Sequential presents a sell signal on the <a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> <a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a> 4-hour chart, anticipating a correction to $0.161 or $0.156! <a href="https://t.co/q8CRhYSZR4">pic.twitter.com/q8CRhYSZR4</a></p>
<p>&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1853737569529331972?ref_src=twsrc%5Etfw">November 5, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>Crypto trader Unipcs expects Dogecoin could go "parabolic" if <strong>Donald Trump </strong>wins the election, foreseeing gains for both DOGE and the similarly named meme asset, &#8216;Department of Government Efficiency&#8217; (D.O.G.E.). He <a href="https://x.com/theunipcs/status/1853757117766705585">likened</a> their current state to "underwater beachballs waiting to explode."</p>
<p>Other commentators in the crypto community <a href="https://x.com/MikybullCrypto/status/1853732020481913019">pointed out</a> Dogecoin&#8217;s first golden cross since Q4 2020 and strength in <a href="https://x.com/AltcoinSherpa/status/1853753655578575014">chart patterns</a>. </p>
<p>Trader Rekt Capital pointed out that Dogecoin recently retested its May highs as new support, suggesting the coin could eventually revisit the $0.20 level.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr"><a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a><br /><br />Dogecoin has also most recently successfully retested the May 2024 highs as new support (blue)<br /><br />Overall, continued stability above blue will continue to position DOGE for a move via the orange pathway to revisit the $0.20 highs (black) over time<a href="https://twitter.com/hashtag/DOGE?src=hash&amp;ref_src=twsrc%5Etfw">#DOGE</a> <a href="https://twitter.com/hashtag/Crypto?src=hash&amp;ref_src=twsrc%5Etfw">#Crypto</a> <a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> <a href="https://t.co/CkqCTH6Dms">https://t.co/CkqCTH6Dms</a> <a href="https://t.co/oEKk87uvu7">pic.twitter.com/oEKk87uvu7</a></p>
<p>&mdash; Rekt Capital (@rektcapital) <a href="https://twitter.com/rektcapital/status/1853803996068089934?ref_src=twsrc%5Etfw">November 5, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong>Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41699095/dogecoin-set-for-parabolic-bull-run-in-november-says-analyst-keep-an-eye-out-for-a-sustain">Dogecoin Set For &#8216;Parabolic Bull Run&#8217; In November, Says Analyst: &#8216;Keep An Eye Out For A Sustained Close&#8217; Above This Level</a></strong></p>
<p>IntoTheBlock data shows large transaction volumes up by 27.2%, with daily active addresses increasing by 13.4% and major transactions over $100,000 rising from 373 to 586 in just one day. Exchanges netflows are down by 173.2%.</p>
<p><strong>What&#8217;s Next</strong>: The influence of meme coins is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.</p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41688358/dogecoin-dips-but-traders-identify-this-critical-support-zone-for-a-bounce">Dogecoin Dips But Traders Identify This Critical Support Zone For A Bounce</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

Dogecoin Skyrockets 11%: What Is Going On?

<p>B. Riley Securities  analyst Mayank Mamtani   maintains Madrigal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) with a Neutral and raises the price target from $194 to $236.</p>


MDGL

B. Riley Securities Maintains Neutral on Madrigal Pharmaceuticals, Raises Price Target to $236

<p>B. Riley Securities  analyst Alex Rygiel   reiterates Landsea Homes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSEA#NASDAQ">LSEA</a>) with a Buy and raises the price target from $17 to $18.</p>


LSEA

B. Riley Securities Reiterates Buy on Landsea Homes, Raises Price Target to $18

<p><a href="https://blogs.nvidia.com/blog/rekor-metropolis-ai-jetson-roadway-safety/">https://blogs.nvidia.com/blog/rekor-metropolis-ai-jetson-roadway-safety/</a></p>
<p>Company Is Introducing AI-Driven Analytics Using NVIDIA AI, Metropolis And Jetson For Texas And Philadelphia Roads That Could Reduce Fatalities And Improve Quality Of Life</p>
<p>&nbsp;</p>
<p>Austin is drawing people to jobs, music venues, comedy clubs, barbecue and more. But with this boom has come a big city blues: traffic jams.</p>
<p>Rekor, which offers traffic management and public safety analytics, has a front-row seat to the increasing traffic from an influx of new residents migrating to Austin. Rekor works with the Texas Department of Transportation, which has a $7 billion project addressing this, to help mitigate the roadway concerns.</p>
<p>"Texas has been trying to meet that growth and demand on the roadways by investing a lot in infrastructure, and they're focusing a lot on digital infrastructure," said Shervin Esfahani, vice president of global marketing and communications at Rekor. "It's super complex, and they realized their traditional systems were unable to really manage and understand it in real time."</p>
<p>Rekor, based in Columbia, Maryland, has been harnessing <a href="https://developer.nvidia.com/metropolis">NVIDIA Metropolis</a> for real-time video understanding and <a href="https://www.nvidia.com/en-us/autonomous-machines/embedded-systems/jetson-xavier-series/">NVIDIA Jetson Xavier NX</a> modules for edge AI in Texas, Florida, Philadelphia, Georgia, Nevada, Oklahoma and many more U.S. destinations as well as in Israel and other places internationally.</p>
<p>Metropolis is an application framework for smart infrastructure development with vision AI. It provides developer tools, including the <a href="https://developer.nvidia.com/deepstream-sdk">NVIDIA DeepStream SDK</a>, <a href="https://developer.nvidia.com/tao-toolkit">NVIDIA TAO Toolkit</a>, pretrained models on the <a href="https://ngc.nvidia.com/catalog">NVIDIA NGC catalog</a> and <a href="https://developer.nvidia.com/tensorrt">NVIDIA TensorRT</a>. <a href="https://www.nvidia.com/en-us/autonomous-machines/embedded-systems/?srsltid=AfmBOoprOO5bpyzSi4PpQOfeWh4mBBe-HWE-wPYsbBKp90XPhV_mSCxr">NVIDIA Jetson</a> is a compact, powerful and energy-efficient accelerated computing platform used for embedded and robotics applications.</p>
<p>Rekor's efforts in Texas and Philadelphia to help better manage roads with AI are the latest development in an ongoing story for <a href="https://blogs.nvidia.com/blog/cvedia-ai-intersects-u-s-traffic-lights-better-flow-safety/">traffic safety</a> and <a href="https://blogs.nvidia.com/blog/city-of-raleigh-metropolis-traffic/">traffic management</a>.</p>


NVDA

REKR

"Austin Calling: As Texas Absorbs Influx Of Residents, Rekor Taps NVIDIA Technology For Roadway Safety, Traffic Relief" - Blog

Andean Precious Metals Corp (APM) is up 1040.96% today. APM has an Overall Score of 67. Find out what this means to you and get the rest of the rankings on APM!See Full APM ReportAPM stock closed at $0.83 and is up $8.64 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as mo

Should You Hold Andean Precious Metals Corp (APM) Stock Wednesday Morning?

JAGX and GNPX among Health Care movers

XTIA, PSNL and LIDR among mid-day movers

Andean Precious Metals Corp (APM) has gained Wednesday morning, with the stock increasing 888.10% in pre-market trading to 8.3. APM's short-term technical score of 55 indicates that the stock has traded more bullishly over the last month than 55% of stocks on the market. In the Biotechnology industry, which ranks 100 out o

Andean Precious Metals Corp (APM) has risen 888.10% Wednesday In Premarket Trading

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>The best <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> to buy are in companies that put a lot of resources into research and development, often with nothing to show for it for years. </p>



<p>Regulatory hurdles make finding biotech stocks to buy challenging if you don&rsquo;t have the patience to wait it out.</p>



<p>But when biotech companies win approval to sell and marketing a drug, the potential for profits can be off the charts. That&rsquo;s why it&rsquo;s a good idea to at least consider biotech, and whether they have a spot in your portfolio.</p>



<p>Biotech stocks represent companies involved in the research, development and commercialization of biological-based products that are designed to improve health. These companies can include pharmaceuticals, biotechnology, medical devices, and healthcare services.</p>



<p>While the industry is challenging because of the regulatory approval process and keen competition, biotech stocks do have some significant advantages. </p>



<p>For example, they are relatively immune to economic downturns. Even when the economy does poorly, people and insurance companies will spend money on monthly medications they need to improve their quality of life. </p>



<p>As the population ages, healthcare spending for pharmaceuticals and other medical products will continue to increase.</p>



<p>We&rsquo;re using the Portfolio Grader to find the best biotech stocks to buy in today&rsquo;s market. Each of these stocks gets top grades.</p>



<h2>Eli Lilly &amp; Co. (LLY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/lly_eli_lilly_1600-300x169.png" alt="Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals XI"><div>Source: Jonathan Weiss / Shutterstock.com</div></div><p>Weight loss drugs are one of the most popular trends in the biotech industry right now, with an estimated <a href="https://www.niddk.nih.gov/health-information/health-statistics/overweight-obesity">42% of the U.S. population</a> considered obese. That&rsquo;s why the first two companies on our list are top picks, both of them are soaring on the strength of their weight loss medications.</p>



<p>The U.S.-based company in this equation is <strong>Eli Lilly &amp; Co.</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/lly-stock-quote/"><strong>LLY</strong></a>), which markets its obesity drug under the name Zepbound. About 1 in 3 people who took the injectable drug at its highest dose (15 mg) report losing more than 58 pounds over a 72-week period.</p>



<p>The drug in Zepbound, tirzepatide, is also used in another highly successful Lilly product called Mounjaro, which is used to treat type 2 diabetes. Analysts believe that Zepbound can eventually be worth $25 billion a year in sales, and that Mounjaro sales could jump from $5.2 billion in 2023 to $16 billion in 2024.</p>



<h2>Novo Nordisk (NVO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/nvo-stock-300x169.jpg" alt="Novo Nordisk logo on a corporate building"><div>Source: joreks / Shutterstock.com</div></div><p>The European entry into this equation is <strong>Novo Nordisk</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/nvo-stock-quote/"><strong>NVO</strong></a>), which has an injectable weight loss drug of its own called Wegovy. Wegovy was approved in 2021 in the U.S. to treat obesity and recently expanded to the U.K.</p>



<p>Expansion came with some growing pains, though. Some pharmacies continue to report shortages, and Novo Nordisk <a href="https://www.novonordisk-us.com/supply-update.html">says</a> its running its manufacturing lines 24 hours a day to try to maintain the supply.</p>



<p>Norvo Nordisk also manufactures the drug Ozempic as a treatment for type 2 diabetes, but doctors have also prescribed it as a treatment for weight loss.</p>



<p>NVO saw <a href="https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=167013">revenue</a> of $21.4 billion in the fourth quarter, up 31% from the previous year. Profits of $7.7 billion were a 51% increase from the previous year.</p>



<p>NVO stock is up 20% in 2024 and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<h2>Corbus Pharmaceuticals (CRBP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/01/crbp1600-300x169.png" alt="Corbus Pharmaceuticals (CRBP) leads in developing innovative drugs to treat inflammatory and fibrotic diseases. Exceptional quality patient focus"><div>Source: MacroEcon / Shutterstock.com</div></div><p><strong>Corbus Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/crbp-stock-quote/"><strong>CRBP</strong></a>) is a Massachusetts-based drugmaker specializing in oncology treatments. The company has potential drugs in its pipeline to treat solid tumors with antibody drug conjugates and monoclonal antibodies.</p>



<p>The most advanced treatment is treating U.S. patients with metastatic urothelial cancer <a href="https://www.corbuspharma.com/press-releases/detail/410/corbus-announces-dosing-of-first-patient-in-u-s-phase-1">in a trial study</a>.</p>



<p>Corbus also started work on a treatment for obesity and related conditions, although trials for that aren&rsquo;t expected to begin until the fourth quarter of this year.</p>



<p>Corbus doesn&rsquo;t have revenue coming in yet, so it&rsquo;s seeing steep losses &ndash; $8 million in the fourth quarter and $44.6 million for the full year. But that&rsquo;s expected for a biotech stock that has drugs in the pipeline but none yet for sale. You have to be willing to ride it out.</p>



<p>Many investors are. CRBP stock is up more than 500% so far this year as the market reacts to positive developments in the company&rsquo;s clinical trials. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<h2>Aptorum Group (APM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/09/apm-stock-1-300x169.jpg" alt="A magnifying glass zooms in on the website for Aptorum Group (APM)."><div>Source: Pavel Kapysh / Shutterstock.com</div></div><p><strong>Aptorum Group</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/apm-stock-quote/"><strong>APM</strong></a>) is a U.K.-based pharmaceutical company developing oncology and infectious diseases treatments. </p>



<p>Its approach includes screening approved drug molecules and using its research platform to seek and develop new treatments and therapies.</p>



<p>The company recently agreed to a <a href="https://www.marketwatch.com/story/aptorum-group-to-merge-with-yoov-group-split-off-legacy-assets-28822b75">reverse merger</a> between its wholly owned subsidiary and <strong>YOOV Group</strong>, specializing in AI techniques to optimize business operations. &nbsp;APM shareholders will own 10% of the combined company after the merger.</p>



<p>Aptorum also plans to split off its legacy business assets into a subsidiary to be called Aptorum Therapeutics.</p>



<p>News of the merger and restructuring turbocharged APM shares, which are now up 264% in 2024. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<h2>Merck &amp; Co. (MRK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/mrk-stock-3-300x169.jpg" alt="Merck (MRK) logo outside of corporate building"><div>Source: Atmosphere1 / Shutterstock.com</div></div><p><strong>Merck &amp; Co.</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/mrk-stock-quote/"><strong>MRK</strong></a>) is a New Jersey-based pharmaceutical company best known for its Keytruda cancer treatment. Keytruda brought in <a href="https://www.fiercepharma.com/pharma/whos-no-1-25b-sales-mercks-keytruda-appears-set-be-top-selling-drug-2023">$25 billion</a> in sales in 2023, making it the top-selling drug in the world.</p>



<p>But Merck also has many other drugs on the market, including Gardasil for human papillomavirus; ProQuad, which is a vaccine for measles, mumps, rubella and chickenpox; and Januvia for type 2 diabetes. And that&rsquo;s important, as Merck will lose exclusivity for Keytruda in 2028, making it available for generic substitutes.</p>



<p>Merck expanded that pipeline last month by <a href="https://www.merck.com/news/merck-completes-acquisition-of-harpoon-therapeutics-inc/">completing its acquisition</a> of Harpoon Therapeutics. The company&rsquo;s lead drug candidate treats small cell lung cancer and neuroendocrine tumors.</p>



<p>Earnings for the <a href="https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2023-financial-results/">fourth quarter</a> included revenue of $14.6 billion, up 6% from a year ago. The company reported a loss of $1.2 billion and 48 cents per share as part of previously announced charges incurred in its deal with <strong>Daiichi Sankyo</strong> to jointly develop three cancer treatments.</p>



<p>MRK stock is up 16% in 2024 and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<h2>Gyre Therapeutics (GYRE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div><p><strong>Gyre Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/gyre-stock-quote/"><strong>GYRE</strong></a>) is a North Carolina-based biotech company developing treatments for organ fibrosis and inflammatory diseases. </p>



<p>The company completed a Phase 2 trial in China for its treatment of hepatitis B-induced liver fibrosis.</p>



<p>It&rsquo;s now planning a Phase 2 trial for the treatment in the U.S. The drug candidate, Hydronidone, is a structural analog of pirfenidone, which is already approved in the U.S. and China for the treatment of idiopathic pulmonary fibrosis.</p>



<p>The company says there are more than 140 million people who have liver fibrosis from hepatitis B, with no approved therapies on the market. So, its treatment has the potential to be profitable for investors.</p>



<p>Gyre posted full-year revenue in 2023 of $113.5 million, up from $102.3 million in 2022.</p>



<p>GYRE stock is up 330% in the last 12 months, but has been falling so far in 2024. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<h2>Neurogene (NGNE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/bio1600-300x169.jpg" alt="MRNA Stock Will Continue Its Slump, but a $25 It Will Be a Great Buy"><div>Source: Shutterstock</div></div><p><strong>Neurogene</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/ngne-stock-quote/"><strong>NGNE</strong></a>) is a biotech company that is developing what it calls EXACT gene therapy technology. </p>



<p>The platform can be used to achieve optimized levels of transgene expression for each drug candidate, which Neurogene says gives it an advantage over traditional gene therapy.</p>



<p>It&rsquo;s currently working with the platform to develop its lead gene therapy candidate for Rett syndrome, which is a disorder seen in children that impairs their ability to walk, eat, speak or breathe.</p>



<p>The company went public just last year in a <a href="https://ir.neurogene.com/news-releases/news-release-details/neurogene-announces-closing-merger-neoleukin-therapeutics-and">reverse merger</a> with cancer drug developer Neoleukin Therapeutics backed by investment firms that put $95 million into the newly formed company. The investment is expected to <a href="https://ir.neurogene.com/news-releases/news-release-details/neurogene-reports-fourth-quarter-and-full-year-2023-financial">assure Neurogene of funding</a> until the second half of 2026.</p>



<p>That gives it a solid window to develop and get approvals.</p>



<p>NGNE stock is up 95% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.</p>



<p><em>On the date of publication, Louis Navellier held LLY and NVO. He did not have (either directly or indirectly) any other positions in the securities mentioned in this article.</em></p>



<p><em>The InvestorPlace Research Staff member primarily responsible for this article did not hold (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/market360/2024/04/7-a-rated-aggressive-biotech-stocks-to-bet-on-in-2024/">7 A-Rated Aggressive Biotech Stocks to Bet On in 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 A-Rated Aggressive Biotech Stocks to Bet On in 2024

CGC, GENE and HOLO among mid-day movers

Aptorum Group (APM) has released an update. Aptorum Group, a biopharmaceutical company, has reported a decreased net loss of $4.3 million for the f...

Aptorum Group Reports Decreased Annual Loss

Aptorum Group reports FY results

Aptorum Group (APM) has released an update. Aptorum Group Limited has announced an amendment to extend the term of its Merger Agreement with YOOV G...

Aptorum Group Extends Merger Agreement Term

Aptorum Group (APM) has released an update. Aptorum Group Limited announced the resignation of two directors, Dr. Mirko Scherer and Mr. Charles Bat...

Aptorum Group Board Sees Key Resignations

AILE

AISP

ALRN

ANGH

ANVS

APAC

AQST

BNTC

BPTH

CRBP

EDBL

FEMY

GENE

GNPX

GYRE

HOLO

ICLK

INLX

JAGX

LFCR

LIDR

MIGI

NGNE

NRXP

PSNL

RETO

RLMD

SINT

SWVL

TFFP

THCH

TOON

TRUG

TSHA

WISA

WORX

WULF

XPON

XTIA

XTLB

Press Releases

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023

Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023

Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business

Comments

Aptorum Gr

Notizie

Ultime notizie per Aptorum Gr (NASDAQ:APM) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO